CompletedPhase 2NCT00112463
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Studying Alveolar soft tissue sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Paul SavageWake Forest University Health Sciences
- Intervention
- romidepsin(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2008
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00112463 on ClinicalTrials.govOther trials for Alveolar soft tissue sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07548177Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part SarcomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1NCT06066138A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06813417CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part SarcomaUniversity of Calgary
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06789081GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)AHS Cancer Control Alberta
- RECRUITINGPHASE2NCT05333458Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM TrialNational Cancer Institute (NCI)
- RECRUITINGNANCT03967834Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma GroupInstitut Claudius Regaud
- RECRUITINGPHASE2NCT04332874A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or LegMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT03016819Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)Advenchen Laboratories, LLC